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Summary 
    Protein kinases are among the most intensively pursued class of drug targets with inhibitors 
of about 30 distinct kinase targets in a Phase I clinical trail. The vast majority of these 
inhibitors are under investigation for the treatment of cancer; however, aberrant kinase 
function has been implicated in further indications, including immunological, neurological, 
metabolic and infectious diseases. To date, 14 kinase inhibitors have been approved by the US 
Food and Drug Administration for the treatment of cancer. 
    This PhD thesis focuses on the identification of novel tyrosine kinase inhibitors by 
computational modeling. Over four years, two programs have been developed to complete the 
virtual screening tool box: Mr. Dock, a fast and accurate flexible-docking tool, and an 
accurate scoring function. A molecular dynamics-based method (MD-IF) was devised to 
circumvent issues relating to induced-fit in docking, thus allowing the protein target to be 
explored by a larger area of chemical space. We further optimized the in silico fragment-
based approach by introducing a new fragmentation tool called LIBO. The developed 
methods have been retrospectively validated, and prospectively lead to the discovery of three 
novel classes of tyrosine kinase inhibitors with activities ranging from low micromolar to 
nanomolar. 
    The first pyrrolo[2,3-b]quinoxaline scaffold identified in silico formed the basis of a series 
of derivatives as tyrosine kinase inhibitors, exhibiting potent enzymatic and cellular activity, 
good solubility, and selectivity profiles comparable to marketed drugs. A second isoquinoline 
scaffold gave rise to a 160 nM lead compound, which is promising for future optimization. 
Finally, predicted binding modes were confirmed by X-ray crystallography, indicating that 
these findings can be ascribed to computational modeling and not serendipity. 
 
Summary 
    Mit ungefär 30 unterschiedlichen Mitgliedern, welche sich aktuell in Phase I – klinischen 
Studien befinden, gehören die Proteinkinasen zu einer Klasse der meist untersuchten 
Wirkstoffziele. Die große Mehrheit dieser Kinasen werden in Bezug auf ihre Rolle in 
Krebserkrankungen untersucht. Dysregulation der Kinasefunktion wird zusätzlich als Faktor 
in immunologischen, neurologischen, metabolischen und infektiösen Krankheiten 
angenommen. Bis heute wurden 14 Kinaseinhibitoren als Krebsmedikamente durch die US 
Food and Drug Administration (FDA) zugelassen.  
    Diese Dissertation hat zum Ziel, neuartige Tyrosinkinase-Inhibitoren mit 
computergestützten Methoden (Computational Modelling) zu identifizieren. In den letzten 
vier Jahren wurde ein breites Spektrum an akkuraten und flexiblen Virtual Screening-
Werkzeugen fertiggestellt und zusammengefasst als Mr. Dock Programm mit akkurater 
Gütekontrolle (Scoring Function). Etabliert wurde ausserdem ein Kontrollmechanismus per 
Moleküldynamik (Molecular Dynamics) um Induced Fit Problematiken, welche im Docking 
häufig auftreten, analysieren und lösen zu können sowie einen größeren chemischen 
Suchraum für die Kinase abzudecken. Desweiteren wurden In-silico fragmentbasierte Ansätze 
um ein neues Molekülfragmentierungsprogramm erweitert, LIBO. Die entwickelten 
Methoden wurden retrospektiv validiert und erzielten, prospektiv, die Identifikation von drei 
neuartigen Tyrosinkinase-Inhibitoren, welche in ihrer Aktivität von mikromolarer bis zu 
nanomolarer Effektivität variierten.  
    Das als erstes identifizierte pyrrolo[2,3-b] quinoxaline Gerüst (Scaffold) führte zu einer 
Reihe an Derivaten, welche potente enzymatische, zelluläre Aktivität, eine hohe Löslichkeit 
sowie ein Selektivitätsprofil, vergleichbar mit etablierten Tyrosinkinase-Inhibitoren, 
aufweisen. Das zweite Isoquinolin-Gerüst führte zu einem 160 nM Mustermolekül (lead) mit 
vielversprechenden Möglichkeiten zur Optimierung. Abschliessend wurden alle Vorhersagen 
durch Röntgenkristallographie (X-ray crystallography) bestätigt, was den Schluss zulässt, 
dass alle Entdeckungen durch die gezielte Anwendung computergestützter Methoden erreicht 
wurden, nicht etwa durch glückliche Zufälle. 
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Introduction 
 
1.1 Role of Kinases in Diseases 
    Protein kinases catalyze the transfer of the γ-phosphate of ATP to protein substrates.  
Phosphorylation usually results in a functional change of the target protein by changing 
enzyme activity, cellular location, or association with other proteins. The human genome 
contains about 500 protein kinase genes and they constitute about 2% of all human genes. Up 
to 30% of all human proteins may be modified by kinase activity, and kinases are known to 
regulate the majority of cellular pathways, especially those involved in signal transduction.1 
Dysregulation of these pathways has been shown to be a causative factor in human diseases, 
making protein kinases one of the most intensively pursued classes of drug targets with about 
30 distinct kinase targets being developed to the level of a Phase I clinical trial.2 The vast 
majority of these targets are being investigated for the treatment of cancer. However, 
dysregulation of kinase function has also been implicated in other disorders, including 
immunological, neurological, metabolic and infectious disease. Since the first small-molecule 
kinase inhibitor Imatinib reached the market in 2001, 14 kinase inhibitors have received US 
Food and Drug Administration approvals as cancer treatments and considerable efforts are 
ongoing to develop selective small-molecule inhibitors for a host of other kinases that are 
implicated in cancer and other diseases. 
1.2 Targeting Kinase Domain by Different Inhibition Mechanism 
    The catalytic activity of protein kinases is mediated by ATP, which binds in a deep cleft 
located between the N- and C-terminal lobes of a single domain. ATP binds in the cleft with 
the adenine ring forming hydrogen bonds with the kinase hinge, the segment connecting the 
N- and C-terminal lobes. The ribose and triphosphate groups of ATP bind in a hydrophilic 
channel extending to the substrate binding site that features conserved residues essential to 
catalysis. All kinases have a conserved activation loop, which is important in regulating 
kinase activity and is marked by conserved DFG and APE motifs at the start and end of the 
loop, respectively. Kinases can assume a large number of conformations with the extremes 
being a conformer that is catalytically competent and usually phosphorylated, and an inactive 
conformer in which the activation loop blocks the substrate binding site or the key 
catalytically residues are repositioned. 
    To inhibit the abnormal activity of kinases that are over expressed in cancer cells, it is then 
quite natural to target the ATP binding site by small molecules, which directly compete with 
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ATP. The majority of small-molecule kinase inhibitors developed so far target the ATP 
binding site of the kinase in its active state, so called type I inhibitors.3 Given the fact that 
ATP binding site is highly conserved among kinases, the intellectual property (IP) landscape 
is highly congested and discovery of an entity chemically distinct from existing prior art 
becomes increasingly difficult. 
    The first small molecule to reach the market was imatinib (Gleevec), a so called type II 
tyrosine kinase inhibitor which binds to the inactive state of Abl1 characterized by a closed 
conformation of the activation loop (DFG-out). The flip of the DFG-motif, a conserved triad 
Asp-Phe-Gly at the beginning of the activation loop, induces remarkable changes in the ATP 
binding site and exposes an additional hydrophobic pocket that is less conserved in sequence.4 
Many type I kinase inhibitors have failed in preclinical or clinical development due to lack of 
selectivity causing intolerable side effects, largely because the ATP binding site is highly 
conserved in sequence and conformation.5 The emergence of type II inhibitors creates new 
opportunities by targeting the allosteric pocket of the DFG-out conformation, offering 
selectivity and intellectual property novelty.6 Bothe type I and II kinase inhibitors are ATP-
competitive, but type II inhibitors further stabilize the kinase in its catalytically inactive state.  
    Compared to type I and II, allosteric inhibitors usually referred to as Type III inhibitors 
bind exclusively to sites outside of the conserved ATP site. Targeting the kinase domain 
outside of the conserved ATP site is regarded as to be an effective strategy to achieve greater 
selectivity, cellular potency and to identify inhibitors with novel IP property. The type III 
inhibitors can be further classified into ATP-competitive and Non-ATP-competitive. The 
ATP-competitive type III inhibitors bind in an allosteric pocket adjacent to the ATP site, and 
indirectly compete with ATP by modifying the shape of the ATP site. The Non-ATP-
competitive type III inhibitors bind in an allosteric site that is distal to the ATP site, and 
inhibit catalysis by: 1) repositioning key catalytic residues; or 2) competing with binding of 
protein/peptide substrate; or 3) binding to regulatory sites or domains that are distal to the 
active site cleft. 
1.3 Ligand-Based Virtual Screening 
    Ligand-based virtual screening firstly can be conducted in a rather intuitive way that is to 
retrieve common features (e.g., hydrogen bonding donors and acceptors) from a set of known 
inhibitors, and further use such information to inquire a compound library. The conventional 
way is to take the binding affinity as a function of physico-chemical properties, topological 
indices and electronic structures of ligands, and then establish a quantitative structure-activity 
relationship (QSAR) from a set of known inhibitors. The more complicated way is to include 
3D conformers of ligands in the derivation of QSAR model. 
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    The nature of ligand-based approach is a guess of atomic protein-ligand interaction from 
the sole part of ligands. When the protein structure is not available, this approach is certainly 
a nice choice among others, if not the best. However, the nature of guess determines its 
ambiguity in screening, leading to a low enrichment factor. The ambiguity in screening on the 
other hand could be an advantage, compared to the precision of structure-based docking 
approach where induced fit is a common issue limiting identification of ligands that could not 
fit into the rigid binding site. 
1.4 Structure-Based Virtual Screening 
    Structure-based approach is to predict the dissociation constant on the atomic level. 
Starting from the thermodynamic definition of the dissociation constant, one would 
immediately propose to simulate the binding/unbinding of ligands from the protein by 
molecular dynamics (MD), and directly calculate the dissociation constant from kinetics 
assuming 1:1 binding: 
)1(/ onoffD kkK =  
Alternatively, equipped with powerful computers, one can even propose to simulate a system 
with multiple copies of proteins and ligands, and directly get the dissociation constant from 
thermodynamic equilibrium: 
)2(]/[]][[ complexligandproteinK D =  
Although molecular dynamics provide a vivid image regarding how ligands bind/unbind at 
the atomic level, it is computationally rather expensive, and it is almost never used in practice 
as a virtual screening means. The MD based free energy perturbation approach such as 
umbrella sampling is computationally more efficient, but still seldom used in practice due to 
its rather slow computational speed and degraded accuracy for molecules with drug-like size.  
)3()ln( DKRTG −=Δ  
)4(STHG Δ−Δ=Δ  
    On the other hand, one can get the dissociation constant from binding free energy (Eq. 3), 
which is a sum of enthalpy ΔH and entropic effect –TΔS (Eq. 4). Entropy is rather difficult to 
compute and quite often has been neglected, while enthalpy as interaction energy between the 
protein and ligand can be easily computed. In the framework of empirical force field, enthalpy 
is the sum of van der Waals interaction energy, electric interaction energy including the 
Columbic energy in vacuo and desolvation energy upon ligand binding, conformational strain 
of the ligand and so on. Given a binding pose of the ligand, the interaction energy can then be 
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easily and quickly computed, which provides an efficient means to predict the binding free 
energy. The primary focus for this approach is to find rational binding modes of ligands, 
which is called docking. The common structure-based approach consists of a docking step and 
a post-scoring step that utilizes a sophisticated energy function to prioritize the ligands, and 
both steps are usually based on a rigid protein structure. 
1.5 Limitations in Current Computational Modeling 
    At first glance, one might be quite optimistic about drug discovery using structure-based 
approach, since the binding free energy can be easily computed. However, this is quite wrong 
if not completely. One has to realize the limitations in current structure-based approach (to 
name a few but not limited to):  
1. The empiric force field is Newton physics based, and is approximate just as “empiric” 
implies. It weakly treats hydrogen bonding and pi-pi packing interaction which plays an 
essential role in ligand binding, and it is simply incapable of handling halogen bonding 
and hypercovalency of sulfur atoms.   
2. Accuracy of the empiric force field is not only determined by the physical models, but 
also the parameters. Errors in experimental data used for parameterization have not been 
systematically reviewed and corrected;  
3. The parameters for small molecules have not been extensively validated.  
4. Most importantly, enthalpy only cannot represent the binding free energy as shown by 
thermodynamic data of 100 protein-ligand interactions.7 In general, protein-ligand 
complexes that exhibit more negative enthalpies of binding do so at the cost of more 
positive –TΔS terms and vice versa. This enthalpy-entropy compensation effect is 
clearly evidenced by the thermodynamic data7 in a way that enthalpy and –TΔS are 
strongly negatively correlated. Due to the absence of the entropic effect in an energy 
function (usually referred to as a scoring function), it inevitably leads to false positives 
when the entropic effects significantly deviate from those in the data set used to train the 
energy function. This becomes more severe for larger molecules, as the enthalpy 
increases with the increase in molecular size given the pairwise additive nature of van 
der Waals interaction while the increasing unfavorable entropic effect is missing. 
Although MD based approaches could in principle rigorously deal with entropic effects, 
computational modeling is just a means to the end for drug designers. So, a drug 
designer would have no reason to use any molecular dynamics based methods if they are 
not comparable to the high throughput screening (HTS) in terms of cost and time 
efficiency, not to mention that essentially all computational approaches so far are 
disappointing inaccurate. 
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1.6 Dance with Shackles on 
    What is the real situation of computational modeling like in current pharmaceutical 
industry? “The more extravagant promises of combichem ended up in the same bin as the 
more extravagant promises of modeling, stored in the basement alongside some dusty but 
snazzy-looking hardware for which no one now can locate the manual”.8 This situation is in 
strong contrast to the prosperous outlook in computational literature. However, one would 
understand the contradiction immediately if one notices that scientific journals only publish 
work where people managed in successful identification of active compounds, a phenomenon 
so called cherry pick in statistics. Serendipity always plays a certain role in the process of 
anything that is called discovery including drug discovery. A computational method with few 
successful prospective applications does not necessarily rule out the role of serendipity, and 
thus does not necessarily demonstrate its utility in practice. 
    However, there is no need to be pessimistic. It would be equally stupid to deny the 
importance of computational modeling, which at this moment is just not as magic as it ever 
promised. To understand its limitations and to complement it with our knowledge would be a 
simple way to be successful in drug discovery compared to the conventional HTS in terms of 
both time and cost, as what will exemplified below. 
1. Hydrogen Bonding Penalty: Hydrogen bonding is one of the most appreciated 
concepts in the field of drug design, but could also be most superficially appreciated in a 
way that most people simply prefer more and stronger hydrogen bonds. However,  
experiment has shown that mutation of Cys-35 in Tyrosyl-tRNA synthetase (TyrTs) to 
Ser-35 caused poorer ATP binding and catalysis although the hydroxyl group of serine 
forms far stronger hydrogen bonds than does the thiol group of cysteine.9 In Chapter 2, 
change in hydrogen bonds during the binding process was reviewed. In an aqueous 
environment, formation of hydrogen bonds between ligand and receptor inevitably is 
accompanied by breakage of hydrogen bonds with water. The enthalpic gain by 
formation of hydrogen bonds is marginal though it is entropically favorable by releasing 
constrained water into the bulk. From the perspective of enthalpy, the formation of 
hydrogen bonds between ligand and receptor does no good, but leads to a potential 
enthalpic loss if the newly formed hydrogen bonds are not in optimal geometry. A 
scoring function with enthalpic penalty in hydrogen bonding was presented, leading to 
the discovery of a novel class of potent, selective and soluble tyrosine kinase inhibitors 
currently under investigation towards clinical application. 
2. An Induced Fit: The phenomenon of induced fit where the ligand binding site alters 
upon binding to become very specific for the given ligand limits the use of the crystal 
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structure in virtual screening campaigns. To circumvent this issue and identify inhibitors 
of tyrosine kinases in their inactive form (DFG-out), a molecular dynamics approach 
was taken in Chapter 3. The computation approach identified a novel chemotype for 
type II kinase inhibitors, which also inhibits the therapeutically relevant T315I mutant of 
Abl1. 
3. In Silico Fragment-Based Approach: Fragment-based drug design approach has seen 
many successful applications in a cost and time efficient way. In Chapter 4, a 
computationally efficient algorithm was introduced to decompose a compound library, 
in order to obtain anchor fragments with high chemical richness that can serve as a 
starting point either directly for hit optimization or for identification of their “parent” 
compounds. The prospective application was illustrated on EphB4 kinase, leading to the 
discovery of a novel chemotype of tyrosine kinase inhibitors. This in silico fragment 
based approach is able to screen the entire compound library in a very efficient way! 
4. Docking: Docking, as computational simulation of a candidate ligand binding to a 
receptor, is used to predict the binding poses of small-molecule drug candidates into 
their protein targets of pharmaceutical relevance, and is the key in structure-based 
virtual screening. In Chapter 5, a new docking software Mr. Dock, standing for 
Molecular Recognition in flexible Docking of small molecules to proteins, was 
presented, and completes our virtual screening “tool box”. 
5. Discovery of Novel ZAP70 Inhibitors: With the complete “tool box”, virtual screening 
now becomes a routine yet boring job, but identification of active pharmaceutical 
ingredients is still struggling.  
6. Deterministic or Serendipity? Is a discovery deterministic or serendipity? This is 
always arguable but certainly a good question to think about. A great discovery is still 
great no matter how it is made, but a computational scientist should care more about the 
general applicability of the methods with careful evaluation of the role of serendipity in 
the discovery. In Chapter 7, the identification of novel EphB4 inhibitors is used as an 
example to initiate the discussion. 
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1.7 Highlights of Discovered Lead Compounds 
Table 1. Lead Compoundsa Derived from Indentified Hits. 
Kineticsb Internal 
Code 
Structure Cellular activity on EphB4 
(nM) KD 
(nM) 
1/koff 
(min) 
ln06 N N
H2N
N
O
OH
930 NDc ND 
lm10 undisclosed <6 6.5 0.24 
ln28 undisclosed 20 35 25 
ln38 undisclosed 18 9.4 157 
aSynthesized by Dr. Karine Lafleur. bBy surface plasma resonance. cNot determined. 
 
 
 
Figure 1. Selectivity profile of lead compounds ln06 and lm10 assayed at 1 µM (small values 
of big red circles indicate strong inhibition). 
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Figure 2. Selectivity profile of lead compounds ln28 and ln38 assayed at 1 µM (small values 
of big red circles indicate strong inhibition). 
 
Figure 3. Inhibitor binding to EphA3 surfaces. Biacore response data for lm10 at four 
concentrations (A) and for ln28 and ln38 both at a concentration of 500 nM (B), along with 
kinetic curve fits in red. 
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Ranking the strength of individual hydrogen bonds in DNA base pairs  
The three hydrogen bonds a, b and c in DNA bases pairs (Scheme S1) were ranked 
according to the hydrogen bonding strength calculated by fhb*(wA + wD). Different approaches 
[1,2,3,4,5,6] showed substantial discrepancy (Table S4). In the case of G-C complex, larger 
discrepancy was observed, presumably because the energies of the three hydrogen bonds are 
very close. However, in the case of A-T complex, five methods including us gave the same 
ordering, with b being the strongest, and all methods predicted c as the weakest. 
 
Probing hydrogen bonds formed with bound water molecules 
Among the interfacial water molecules observed in the HIV-protease-ligand complexes, 
Water 301 has been found to bridge the gaps between flaps of HIV-1 protease and inhibitors. 
This water molecule forms two hydrogen bonds with NH groups of Ile50 and Ile150 as an 
acceptor, meanwhile forms two additional hydrogen bonds with the carbonyl groups of the 
inhibitor as a donor (Fig. S7). Water 301 is observed in nearly all HIV-1 protease-ligand 
complexes, except in the case it is displaced deliberately [7].   
To see whether the parameters employed can rigorously probe hydrogen bonds formed with 
implicit bound water molecules, four HIV-1 protease crystal structures were tested. As 
illustrated in Fig. S7, each of the four polar atoms forming hydrogen bonds with Water 301 is 
water accessible, and the calculated water molecules meet at the position of Water 301, 
indicative of one water molecule bridging all the four polar atoms. The number of predicted 
dots as potential water positions also represents the entropy of the water molecule. Compared 
with the other two crystal water molecules, the number of predicted dots for Water 301 is 
fewer, consistent with the fact that Water 301 is highly constrained. Hydrogen bonding 
penalty for each complex as well as partial contribution from the protein and ligand was given 
in Table S3. Only one of the catalytic aspartyl diad (Asp25 and Asp125) was deprotonated, as 
evidenced by NMR study [8]. 
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Scheme S1. H-bonded complexes of nucleic acid pairs 
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Scheme S2. Schematic view of probing hydrogen bonds formed with implicit water. Three 
shells around each donor or acceptor were generated with the radius being rsol-0.15, rsol, and 
rsol+0.15 Å, respectively. In the current study, 2200 dots were distributed over the surface of 
each shell, with each dot representing the probability of a hydrogen bond with implicit water. 
Dots with the angle Θ less than 90o or within the inner shell of other atoms will be removed. 
Any dot left indicates hydrogen bonding with water remains.  
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Table S1. MPEOE partial charge and water solubility of model small molecules used to 
generate initial guess of hydrogen bonding weights. 
 MPEOE partial charge (e) Solubility in water at 20 oC 
pyridine N (-0.58) miscible 
N-methylacetamide O (-0.56); H (0.26) N.A. 
acetone O (-0.49) miscible 
aniline H (0.27) 3.6 g/100ml 
n-propanol O (-0.62); H (0.39) miscible 
n-butanol O (-0.62); H (0.39) 7.7 g/100ml 
phenol O (-0.59); H (0.40) 8.3 g/100ml 
diethyl ether O (-0.37) 6.9 g/100ml 
 
 
Table S2. Two-parameter LIECE energy and hydrogen bonding penalty on 24 EphB4 
inhibitors [9]. 
No. PHB 
(kcal/mol) 
LIECE 
(kcal/mol) 
Exp. ΔG 
(kcal/mol) 
No. PHB  
(kcal/mol) 
LIECE 
(kcal/mol) 
Exp. ΔG 
(kcal/mol) 
8 1.05 -12.52 -7.93 20 1.04 -12.73 -7.79 
9 1.03 -12.39 -7.23 21 1.09 -12.06 -6.40 
10 1.07 -12.74 -8.10 22 1.05 -12.82 -8.54 
11 1.02 -12.60 -7.69 23 1.01 -12.74 -8.05 
12 1.09 -12.78 -6.75 24 1.49 -12.72 -6.07 
13 1.04 -13.08 -8.02 25 1.05 -12.87 -10.09 
14 1.02 -12.81 -7.12 26 1.03 -12.74 -8.90 
15 2.09 -12.98 -6.62 27 1.43 -12.95 -5.99 
16 1.04 -12.99 -8.65 28 1.02 -13.44 -9.61 
17 1.04 -12.78 -7.91 29 1.05 -13.22 -8.46 
18 1.31 -12.94 -7.38 31 1.03 -13.98 -8.51 
19 1.03 -13.01 -8.45 32 1.06 -13.46 -8.19 
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Table S3. Hydrogen bonding penalty of HIV-1 protease complexes. 
PHB   
PDB code 
 
Resolution (Å) Protein Ligand Total 
1HXW 1.80 0.70 0.68 1.38 
1HXB 2.30 0.58 0.66 1.23 
1HPX 2.00 1.00 0.56 1.56 
1HIH 2.20 1.04 0.11 1.16 
 
 
 
Table S4. Ranking of the individual H-bonds strengths in the G-C and A-T base pairs 
(Scheme S1) on the basis of literature data and our results. 
Method of characterizing the H-bonds Calculation level G-C A-T 
Rotation [1] B3LYP/D95** c>b>a a>b>c 
Compliance constants [2] B3LYP/6-311++G** b>a>c b>a>c 
Atom replacement [3] B3LYP/6-311++G** a>c>b b>a>c 
EML equation [4] for experimental geometry B3LYP/6-311++G** a>b>c a>b>c 
EH…B vs. ρCP relation [5] B3LYP/6-311++G** a>c>b b>a>c 
NBO[6] B3P86/6-311++G** a>b>c b>a>c 
Hydrogen bonding weights N.A. b>a=c b>a>c 
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Table S5. Hydrogen bonding penalty of the 100 kinase complex structures.  
Protein PDB code PHB Protein PDB code PHB Protein PDB code PHB 
1gz8 0.38 1iep 1.23 1ove 1.02 
1h0v 0.71 3kfa 1.57 1oz1 0.00 
1h0w 0.47 1opj 1.12 1w82 1.16 
3lfn 1.04 2f4j 1.83 1w84 0.21 
3lfq 0.24 2g2h 1.50 1yqj 0.00 
3lfs 0.71 2gqg 0.51 1ywr 1.11 
3ig7 0.06 3dk3 0.52 1zzl 1.27 
3igg 0.26 3dk6 0.52 3gc7 0.02 
1aq1 0.45 3cs9 0.22 3gcq 0.90 
1e1v 0.74 2qoh 0.61 3flq 1.01 
1e1x 0.71 2v7a 0.48 3fls 1.00 
1jvp 1.16 2z60 0.77 
 
 
 
 
 
p38α 
3flw 1.01 
1h1r 1.57 2e2b 1.47 AurA 3d15 1.11 
2r3f 0.49 2hyy 1.34  2c6e 1.76 
2r3h 0.11 2hz0 0.73  3d2k 1.12 
3le6 0.05 
 
 
 
 
 
 
 
 
 
Abl 
2hzi 1.50  3dj6 0.80 
 
 
 
 
 
 
 
 
 
CDK2 
1ke5 0.70 3bym 2.06  3e5a 1.00 
2vwu 1.51 3bys 0.21  3d14 1.20 
2vwx 1.18 2of2 0.83  3daj 0.00 
2vwy 1.96 2ofu 1.90 3bel 1.00 
2vwz 0.95 2ofv 0.54 1xkk 0.20 
2vx0 0.90 2og8 0.74 
 
EGFR 
2rgp 1.58 
2vx1 0.98 
 
 
 
Lck 
1qpj 0.99 2oo8 0.53 
2vwv 1.18 3e62 0.13 
Tie2 
2p4i 0.96 
 
 
 
EphB4 
2vww 0.96 3e63 0.02 2x4z 1.02 
1pmn 1.92 3e64 0.52 
PAK4 
2cdz 0.10 
1pmv 0.30 3iok 1.19 1t46 1.70 
2b1p 0.16 3kck 0.56 
Kit 
2oiq 0.12 
2ok1 0.27 3jy9 0.29 3gen 0.81 
2p33 1.29 
 
 
 
JAK2 
3lpb 2.01 
BTK 
3k54 1.02 
2r9s 0.32 2x2l 0.00 1qcf 0.61 
3g90 2.04 2ivu 1.08 
Hck 
2hk5 0.28 
3fi3 0.39 2ivv 0.41 
 
 
 
 
JNK3 
3g9l 1.46 
 
Ret 
2x2m 0.11 
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Figure S1. Scatter plot of C―H···O angles against H···O distances in short C―H···O 
interactions between ligands and proteins. 
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Figure S2. Distribution of distances between crystal water oxygen and oxygen or nitrogen 
atoms of proteins. 
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Figure S3. Distribution of some key properties of the inhibitors used in the training and test 
set. 
 
Figure S4. 2D plot of the binding mode of Imatinib. Upon ligand binding, one nitrogen atom 
of the Imatinib pyrimidine ring (N1) becomes water inaccessible and does not form a new 
hydrogen bond, leading to a penalty of 1. By contrast, the other nitrogen atom (N2) remains 
hydrogen bonding with a nearby bound water molecule and thus has no penalty. 
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Figure S5. Poses with the most favorable binding energy of inhibitors of CDK2 (A), EphB4 
(B), p38 α (C), Braf (D) and another set of p38α inhibitors (E). The molecules with bonds in 
red are the binding modes of the corresponding scaffolds in the crystal structures.  
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Figure S6. Distribution of predicted binding affinities by Autodock4 (black) and the proposed 
scoring function (red) on 74,678 compounds passing the first two filters (HB to Met696 and 
PHB ≤ 2 kcal/mol). Bin size: 0.1 kcal/mol. 
 
 
 
 
 
Figure S7. Cartoon representation of HIV-1 protease ligand site (1HIH) with crystal (red 
dots) and calculated (green) water oxygen atoms. 
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Figure S8. Number of donors/acceptors against molecular weight of inhibitors complexed in 
the 100 kinase crystal structures. Colored according to hydrogen bonding penalty. 
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Figure S9. Statistics of hydrogen bonding penalty on the 100 kinase complexes. 
 
Page | 30                                                2. A Scoring Function with Hydrogen Bonding Penalty 
References 
1. Asensio A, Kobko N, Dannenberg JJ (2003) Cooperative hydrogen-bonding in adenine-thymine and guanine-
cytosine base pairs. Density functional theory and Moller-Plesset molecular orbital study. Journal of Physical 
Chemistry A 107: 6441-6443. 
2. Grunenberg J (2004) Direct assessment of interresidue forces in Watson-Crick base pairs using theoretical 
compliance constants. J Am Chem Soc 126: 16310-16311. 
3. Dong H, Hua W, Li S (2007) Estimation on the individual hydrogen-bond strength in molecules with multiple 
hydrogen bonds. J Phys Chem A 111: 2941-2945. 
4. Matta CF, Castillo N, Boyd RJ (2006) Extended weak bonding interactions in DNA: pi-stacking (base-base), 
base-backbone, and backbone-backbone interactions. J Phys Chem B 110: 563-578. 
5. Ebrahimi A, Khorassani SMH, Delarami H (2009) Estimation of individual binding energies in some dimers 
involving multiple hydrogen bonds using topological properties of electron charge density. Chemical Physics 
365: 18-23. 
6. Szatylowicz H, Sadlej-Sosnowska N (2010) Characterizing the Strength of Individual Hydrogen Bonds in 
DNA Base Pairs. J Chem Inf Model. 
7. Lam PY, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, et al. (1994) Rational design of potent, bioavailable, 
nonpeptide cyclic ureas as HIV protease inhibitors. Science 263: 380-384. 
8. Wang YX, Freedberg DI, Yamazaki T, Wingfield PT, Stahl SJ, et al. (1996) Solution NMR evidence that the 
HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the 
asymmetric drug KNI-272. Biochemistry 35: 9945-9950. 
9. Bardelle C, Cross D, Davenport S, Kettle JG, Ko EJ, et al. (2008) Inhibitors of the tyrosine kinase EphB4. Part 
1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg Med Chem Lett 
18: 2776-2780. 
 
3. An Induced Fit of the Receptor by Molecular Dynamics                                           Page | 31 
 
 
Chapter 3 
 
Discovery of Tyrosine Kinase Inhibitors by Docking into an 
Inactive Kinase Conformation Generated by Molecular Dynamics  
 
 
Page | 32                                           3. An Induced Fit of the Receptor by Molecular Dynamics 
 
3. An Induced Fit of the Receptor by Molecular Dynamics                                           Page | 33 
Page | 34                                           3. An Induced Fit of the Receptor by Molecular Dynamics 
 
3. An Induced Fit of the Receptor by Molecular Dynamics                                           Page | 35 
Page | 36                                           3. An Induced Fit of the Receptor by Molecular Dynamics 
 
3. An Induced Fit of the Receptor by Molecular Dynamics                                           Page | 37 
Page | 38                                           3. An Induced Fit of the Receptor by Molecular Dynamics 
 
 
3. An Induced Fit of the Receptor by Molecular Dynamics                                           Page | 39 
Page | 40                                           3. An Induced Fit of the Receptor by Molecular Dynamics 
 
Supporting Information  
 
 
Table S1. Affinity of 5-(piperazine-1-yl)isoquinoline derivatives measured by phage display-
based binding assay.a 
N
N NH+
O
NH
O2N
3
4
2
5
6
 
Kinase  
Substituents 
 
2 3 4 5 6 
EphA3 
wild type 
Abl1 
wild type 
Abl1-
unphosph.  
 wild type 
Abl1-
unphosph. 
T315I 
5 H Cl OCHF2 H H 53 >65 12 45 
6 H Br H H H 63 >65 48 >65 
7 H Cl CH3 H H 61 >65 48 >65 
13 Cl H H Cl H >65 >65 >65 >65 
14 H H N(CH3)2 H H >65 >65 65 >65 
15 F H H H H 58 >65 >65 >65 
16 OCH3 H OCH3 Cl H >65 >65 >65 >65 
17 H F H F H >65 >65 >65 >65 
18 H Cl H H H 60 >65 54 >65 
19 H OCH3 OCH3 H H >65 >65 >65 >65 
N
N NH+
O
NH
O2N
3
4
2
5
6
 
 2 3 4 5 6     
8b H CF3 H H H >65 >65 2.8  
[3.9 µM] c 
5.8 
9b H Cl OCH3 H H >65 >65 28 >65 
10b H Cl F H H >65 >65 38 >65 
11b H Cl H H H 60 >65 21 55 
20b CH3 H H Cl H >65 >65 >65 >65 
21b F H H H F >65 >65 >65 >65 
22b H CH3 H H OCH3 >65 >65 >65 >65 
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N
N NH+
O
NH
O2N
2 3
4
5
6
 
 2 3 4 5 6     
23b Cl H H H CH3 >65 >65 >65 >65 
24b CH3 H H CH3 H 61 >65 >65 >65 
25 CH3 H H H H >65 >65 >65 >65 
26 OCH3 H H H H >65 >65 >65 >65 
27 OCF3 H H H H >65 >65 >65 >65 
28b OCH3 H H H CH3 >65 >65 >65 >65 
aPercentage of kinase not displaced by the test compounds at 30 µM concentration with small 
values indicating high affinity. bCompounds are racemic mixtures as purchased, and checked 
by in-house ESI-MS. cThe Kd value in parentheses is mean of two dose response 
measurements of 11 points each with Kd of 3.8 µM and 4.0 µM, respectively. 
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Figure S1. Time evolution of the dihedral angle χ1 of Tyr742 in 10 explicit solvent MD 
simulations of EphA3 (3DZQ), in the presence of trifluoromethyl-benzene in the allosteric 
site. The χ1 value around -175o corresponds to the orientation in the crystal structure (3DZQ). 
The percentage of snapshots with χ1 close to -175 and -60 is 57% and 43%, respectively. Note 
that the variability in the number of transitions in different runs is a consequence of the 
stochastic character of the side chain rotation which is governed by an activation energy 
barrier. 
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Figure S2. Illustration of the geometric constraints in pharmacophore tailoring ZINC 
compounds library. Donor vector is defined as from the donor heavy atom to the attached 
hydrogen atom. Acceptor vector is defined as that bisects the angle centered at the acceptor 
and points to the lone pair or from carbon to oxygen in the case of carbonyl oxygen. 
Pharmacophore geometric constraints based on known type II inhibitors and the geometry of 
the binding site are: 
1. Capability to form bi-dentate hydrogen bond with the hinge. The angle between the donor 
and acceptor vector is less than 90 degree, and the distance between the donor hydrogen 
and the acceptor is less than 2.9 Å. 
2. In case of forming bi-dentate hydrogen bond, acceptor-donor hydrogen vector dA-H is 
defined as from the acceptor to the donor hydrogen. 
3. The centroid of each hydrophobic ring is constrained by |d| and d·dA-H/|dA-H|, wherein d is 
a vector from the acceptor (red circle) to the centroid. Specifically, for ring in the front 
site |d|<4.5 Å and |d·dA-H|·|dA-H|-1<2 Å; for the ring in the back site 4 Å<|d|<10 Å and 
d·dA-H>0; for the ring in the allosteric site |d|>11 Å and d·dA-H>0;  
4. For the additional acceptor (pink circle) 6 Å<|d|<11 Å and d·dA-H>0. 
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Figure S3. Explicit solvent MD validation of binding mode of compound 5. (Left) MD run 
started from the X-ray structure of the complex between EphA3 and inhibitor 1 (PDB code 
3DZQ). (Right) MD run started from the docked pose of compound 5 into the MD-IF 
structure of EphA3. (Top) Two-dimensional illustrations; (Bottom) time evolutions of 
hydrogen bonding distances measured between donor and acceptor atoms. Note that values 
around 5 Å reflect single water bridged hydrogen bonds with Glu670. Note also that these 
runs used different random numbers for the generation of initial set of velocities than those in 
Figure 6 of the main text. 
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Figure S4. Snapshots from two MD simulations with inhibitor 1. Snapshot from the 
simulation in Figure 6 at about 230 ns (A) and from Figure S3 at 150 ns (yellow) with the one 
in X-ray structure (green). In A, the linker amide group was flipped by 180o. In B, the G-loop 
showed significant conformational change compared to the X-ray structure. 
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Figure S5. Time evolutions of the heavy atom root-mean-square deviation (RMSD) of 
compound 1 (left) and 5 (right) upon overlapping the binding site Cα atoms to the EphA3 X-
ray structure and MD-IF structure, respectively. In one of the two simulations with compound 
1 (left bottom, also shown in Figures S3 and S4), the G-loop is displaced with respect to the 
hinge and the isoxazole group of compound 1 moves away from the hinge after about 50 ns. 
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Synthesis of Compound 7 
    All reagents were used as received unless otherwise noted. Solvents were purchased in the 
best quality available, degassed by purging thoroughly with nitrogen and dried over activated 
molecular sieves of appropriate size. Alternatively, they were purged with argon and passed 
through alumina columns in a solvent purification system (Innovative Technology). Reactions 
were monitored by thin layer chromatography (TLC) using Merck TLC silica gel 60 F254. 
Flash column chromatography was performed over silica gel (230-400 mesh). NMR spectra 
were recorded on AV2 400 or AV2 500 MHz Bruker spectrometers. Chemical shifts are given 
in ppm. The spectra are calibrated to the residual 1H and 13C signals of the solvents. 
Multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), 
doublet-doublet (dd), quintet (quint), septet (sept), multiplet (m), and broad (br). Melting 
points were determined on a Büchi Melting Point B-540 instrument. The purity of all tested 
compounds was determined by HPLC on a Waters Acquity UPLC (Waters, Milford, USA) 
Top spectrometer using an Acquity BEH C18 HPLC column (1.7 µm, 1x50 mm, Waters) with 
a mixture of H2O + 0.1% HCOOH (A) and CH3CN + 0.1% HCOOH (B) solvent (0.1 ml flow 
rate, linear gradient from 5 to 98% B within 4 min followed by flushing with 98% B for 1 
min). UV detection was set to 200-260 nm. 
 
2-Hydroxycyclohex-1-enecarboxylic acid (9) 
OH
CO2H
 
    Ethyl 2-oxocyclohexanecarboxylate (1 mL, 6.3 mmol) was added to a solution of NaOH 
(275 mg, 6.9 mmol) in water (12 mL) at 0 °C. The resulting reaction mixture was stirred 
under ice-cooling for 3 h, and at room temperature for 12 h. The aqueous solution was washed 
with ether and acidified with concentrated HCl under ice cooling. The mixture was stirred for 
45 min, and the formed precipitate was filtered off and dried to afford the expected product as 
a white solid (549 mg, 61%). 1H NMR (300 MHz, CDCl3): δ = 11.98 (s, 1H), 2.32-2.25 (m, 
4H), 1.75-1.59 (m, 4H), OH not observed; 13C NMR (100 MHz, CDCl3): δ = 176.3, 174.7, 
97.1, 29.3, 22.4, 22.3, 21.8; IR (film): υ~ = 3005, 2940, 2860, 1639, 1584, 1434, 1210, 795 
cm-1; MS (ESI): m/z: calcd for C7H9O3-: 141.2, found: 140.9. 
 
2,2-Dimethyl-5,6,7,8-tetrahydro-4H-benzo[d][1,3]dioxin-4-one (10) 
 
    To a solution of 2-hydroxycyclohex-1-enecarboxylic acid (406 mg, 2.8 mmol), acetone 
(417 µL, 5.6 mmol) and acetic anhydride (582 µL, 6.1 mmol) at -5 °C was added 
concentrated sulfuric acid (36 µL, 0.7 mmol). The reaction was stirred at 0 °C for 4 h, poured 
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into a 10% solution of Na2CO3, and extracted with ether. The organic layer was dried over 
MgSO4, filtered, and concentrated under reduced pressure to afford the desired product as a 
colorless solid (484 mg, 93%). 1H NMR (500 MHz, CDCl3): δ = 2.29 (tt, J = 6.2 Hz, J = 1.8 
Hz, 2H), 2.18 (tt, J = 6.3 Hz, J = 1.8 Hz, 2H), 1.76-1.71 (m, 2H), 1.69-1.66 (m, 8H); 13C 
NMR (100 MHz, CDCl3): δ = 164.8, 162.0, 105.1, 102.2, 27.4, 25.1, 21.9, 21.6, 21.1; IR 
(film): υ~ = 2996, 2939, 2859, 1719, 1649, 1401, 1296, 1202, 1024, 760 cm-1; MS (ESI): m/z: 
calcd for C10H14O3Na+: 205.1, found: 205.0. 
 
N-(5-Methoxy-2-methylphenyl)-2-oxocyclohexanecarboxamide (11) 
 
    A mixture of 2,2-dimethyl-5,6,7,8-tetrahydro-4H-benzo[d][1,3]dioxin-4-one (457 mg, 2.5 
mmol) and 5-methoxy-2-methylaniline (343 mg, 2.5 mmol) in o-xylene (8 mL) was subjected 
to microwave irradiation for 5 min at 150 °C. The reaction mixture was cooled down, and the 
resulting precipitate removed by filtration over celite. The mixture was extracted with EtOAc 
and washed with HCl 10%. The organic layer was dried over MgSO4, filtered, and 
concentrated under reduced pressure. Purification by column chromatography (gradient 
toluene/EtOAc 10:0 to 10:1) afforded the desired product as a white solid (308 mg, 46%). 1H 
NMR (500 MHz, CDCl3): δ = 9.41 (s, 1H), 7.73 (d, J = 2.6 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 
6.61 (dd, J = 8.4 Hz, J = 2.6 Hz, 1H), 3.79 (s, 3H), 3.35 (ddd, J = 11.1 Hz, J = 5.5 Hz, J = 0.9 
Hz, 1H), 2.66-2.63 (m, 1H), 2.54-2.43 (m, 2H), 2.27 (s, 3H), 2.14-2.10 (m, 1H), 2.05-1.93 (m, 
2H), 1.87-1.77 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 212.0, 167.0, 158.3, 136.8, 130.8, 
119.9, 110.7, 107.3, 55.6, 55.4, 42.5, 32.4, 27.6, 24.7, 17.0; IR (film): υ~ = 3227, 3122, 2939, 
1709, 1496, 1281, 1122, 1037, 803 cm-1; HRMS (ESI): m/z: calcd for C15H19NO3Na+: 
284.1257, found: 284.1257. 
 
 
3-Amino-2-(5-methoxy-2-methylphenyl)-1-oxo-1,2,5,6,7,8-hexahydroisoquinoline-4-
carbonitrile (12) 
 
    A mixture of N-(5-methoxy-2-methylphenyl)-2-oxocyclohexanecarboxamide (280 mg, 1.1 
mmol), malononitrile (141 mg, 2.1 mmol), piperidine (63 µL, 0.6 mmol) in EtOH (3 mL) was 
heated to 100 °C for 2 h. The reaction mixture was cooled down, and the resulting precipitate 
was filtered off, affording the expected product as a white solid (273 mg, 82%). 1H NMR 
(500 MHz, CDCl3): δ = 7.32 (d, J = 8.5 Hz, 1H), 6.98 (dd, J = 8.5 Hz, J = 2.3 Hz, 1H), 6.68 
(d, J = 2.3 Hz, 1H), 4.67 (s, 2H), 3.80 (s, 3H), 2.67-2.65 (m, 2H), 2.45-2.43 (m, 2H), 2.04 (s, 
3H), 1.81-1.73 (m, 4H); 13C NMR (125 MHz, CDCl3): δ = 160.7, 159.3, 152.3, 147.1, 133.8, 
132.7, 127.8, 117.2, 116.5, 116.2, 113.1, 72.1, 55.5, 28.2, 22.9, 22.0, 21.8, 16.3; IR (film): 
υ~ = 3419, 3308, 3208, 2869, 2202, 1662, 1606, 1531, 1448, 1242, 842 cm-1; HRMS (ESI): 
m/z: calcd for C18H19N3O2Na+: 332.1370, found: 332.1370. 
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1-Amino-5-(5-methoxy-2-methylphenyl)-7,8,9,10-tetrahydropyrimido[4,5-c]isoquinolin-
6(5H)-one (13) 
 
    3-Amino-2-(5-methoxy-2-methylphenyl)-1-oxo-1,2,5,6,7,8-hexahydroisoquinoline-4-
carbonitrile (260 mg, 0.8 mmol) was dissolved in formamide (2.6 mL), and the resulting 
solution was heated to 210 °C for 7 h. The reaction was poured into ice water, and the 
resulting solid was filtered off. Purification by column chromatography (gradient 
EtOAc/CH2Cl2 1:1 to 2:1) afforded the expected product as a white solid (180 mg, 63%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.02 (s, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.11 (s, 2H), 6.89 
(dd, J = 8.4 Hz, J = 2.6 Hz, 1H), 6.65 (d, J = 2.6 Hz, 1H), 3.71 (s, 3H), 3.04-3.03 (m, 2H), 
2.47-2.46 (m, 2H), 1.76 (s, 3H), 1.73-1.70 (m, 4H); 13C NMR (125 MHz, DMSO-d6): δ = 
161.0, 160.5, 158.0, 155.7, 153.7, 143.1, 137.9, 130.7, 126.9, 125.9, 114.1, 113.5, 97.6, 55.2, 
28.6, 24.4, 21.9, 20.7, 16.3; IR (film): υ~ = 3421, 3144, 2941, 1626, 1532, 1216, 1032, 805 
cm-1; HRMS (ESI): m/z: calcd for C19H20N4O2Na+: 359.1479, found: 359.1479. 
 
1-Amino-5-(5-hydroxy-2-methylphenyl)-7,8,9,10-tetrahydropyrimido[4,5-c]isoquinolin-
6(5H)-one (7) 
 
    To a solution of 1-amino-5-(5-methoxy-2-methylphenyl)-7,8,9,10-tetrahydropyrimido[4,5-
c]isoquinolin-6(5H)-one (127 mg, 0.4 mmol) in CH2Cl2 (4 mL) was added BBr3 (1 M, 944 µL
, 0.9 mmol). The reaction was stirred at 25 °C for 16 h, and poured into MeOH. The reaction 
mixture was evaporated several times EtOH, triturated with EtOAc, and the precipitate was fil
tered off. Recrystallization in EtOH and CH2Cl2 afforded the expected product as a white soli
d (34 mg, 28%). mp 262-265 °C; 1H NMR (400 MHz, DMSO-d6): δ = 9.33 (s, 1H), 8.04 (s, 1
H), 7.15-7.09 (m, 3H), 6.72 (dd, J = 8.2 Hz, J = 2.5 Hz, 1H), 6.41 (d, J = 2.5 Hz, 1H), 3.07-3.
01 (m, 2H), 2.46-2.43 (m, 2H), 1.74-1.71 (m, 7H); 13C NMR (125 MHz, DMSO-d6): δ = 160.
9, 159.7, 155.9, 154.7, 153.5, 142.9, 137.4, 130.7, 126.3, 125.0, 115.4, 115.0, 97.6, 28.6, 24.4,
 21.9, 20.7, 16.3; IR (film): υ~ = 3415, 3138, 2936, 2860, 1622, 1525, 1450, 1300, 1208, 804 c
m-1; HRMS (ESI): m/z: calcd for C18H18N4O2Na+: 345.1322, found: 345.1323. HPLC purity 8
8.4%. 
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Protein Expression and Purification 
    A clone of the EphA3 kinase domain (residues: 606-947) was obtained from Prof. Sirano 
Dhe-Paganon’s group1 and expressed in Escherichia coli strain BL21 (DE3). Cells expressing 
EphA3 were induced with a 1 mM solution of isopropyl-beta-D-thiogalactopyranoside (IPTG) 
for 12 h at 15 °C. Cell pellets were resuspended in buffer A (50 mM Tris, pH 8.0, and 100 
mM NaCl, supplemented with protease inhibitors) and lysed by sonication. After 
centrifugation at 15,000 rpm for 1 h, the soluble fraction of EphA3 was purified using 
HisTrap FF crude and HiTrap Q HP columns (GE Healthcare), followed by gel filtration 
chromatography (Superdex75; GE Healthcare). The appropriate fractions were combined and 
concentrated to ~10 mg/mL using Amicon filter devices (10 kDa as cutoff) in a storage 
solution (100 mM sodium chloride and 10 mM Tris-HCl pH 8.0, 5% glycerol). The resulting 
solution was aliquoted and stored at -80 °C for further usage. 
 
Crystallization, Data Collection, and Structure Determination 
    Crystals of the EphA3 kinase domain were grown at 20 °C using the hanging drop vapor 
diffusion method. A 5 mM compound 7 (in 100 % DMSO) was added into the EphA3 protein 
to reach a final DMSO concentration of 10% (v/v) and the mixture was incubated on ice for 1 
hour before crystallization. Then equal volumes of protein (with compound 7) and reservoir 
solutions (0.1 M sodium cacodylate pH 6.5, 0.15 M ammonium sulfate, 22.5% PEG 3350) 
were mixed and crystals appeared after 1 to 2 days. The crystals were flash-frozen in liquid 
nitrogen without extra cryoprotectant for measurements. 
 
Crystallography 
    Data sets were collected on a PILATUS 2M detector at the Swiss Light Source beamline 
X06DA of the Paul Scherrer Institute (Villigen, Switzerland) and indexed, integrated and 
scaled with the XDS2 and CCP43 programs. The structures were solved by molecular 
replacement with PHASER4 using the apo EphA3 kinase domain structure (PDB entry 2GSF) 
as a search model and refined with PHENIX5. 
 
 
Space group P1 21 1 
Unit cell   
a (Å)   53.07 
b (Å)   38.24 
c (Å)   75.84 
alpha   90.00 
beta   101.59 
gamma  90.00 
Resolution range (Å)  47.29 -1.70 
Unique reflections  33115(4694) 
 
 
 
 
<I/σ(I)>   24.5(4.3) 
R merge   0.044(0.416) 
Completeness (%)  99.6(97.8) 
Multiplicity   6.6(6.1) 
Refinement 
 Resolution range (Å)  39.07-1.70 
 R factor/R free  0.179/0.208 
 Mean B factors (Å2)  26.40 
 RMS bonds (Å)  0.0106 
 RMS angles (°)  1.510 
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Figure S1. Previously reported Eph inhibitors. 1, 6-13 The values next to the compound number 
are the Tanimoto similarity index calculated by MACCS keys with compound 7. Compound 
S04, S05 and S09 were discovered by our in silico approach.9-10, 13 
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Figure S2. Decomposition of a known type II kinase inhibitor (PDB entry 1KV1) into anchor 
fragments. Over-decomposition could lead to very small fragments (top, right). Here, the 
following protocol is used to generate anchor fragments by decomposition of a compound 
library. Firstly, all rotatable bonds of a molecule are broken to obtain initial ring systems. 
Secondly, each ring system is extended at the cut until it reaches another ring or the length of 
the extension (number of heavy atoms) reaches three. In case the atom on the third level is not 
an sp3 carbon, the elongation goes further until it reaches an sp3 carbon or a ring. Thirdly, to 
keep the valence unchanged, hydrogen atoms are attached to carbon atoms while heteroatoms 
are capped by CH3 groups. Lastly, to remove identical anchor fragments, a fingerprint 
consisting of molecular formula, number of rotatable bonds, acceptors and donors, and two 
2D topological indices, i.e. modified Wiener14 and Randic15 index, is computed. The Wiener 
index is modified by taking valence and element difference into account as W = 
∑(viei∑(dijej)), wherein vi is the valence of the ith atom minus the number of hydrogen atoms 
attached to it, ei is the atomic number, and dij is the distance between the ith and jth atom in the 
molecular graph. The modified Randic first and second index are 1χ = ∑pipj and 2χ = ∑pipjpk, 
respectively, with pi = ∑dij.  
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Figure S3. Distribution of physicochemical properties of the library of anchor fragments 
(563,774 fragments) obtained by decomposing the ZINC all-now compound library (9 million 
molecules) within 3 hours on a single commodity CPU by the in house developed software 
LIBO. The program LIBO is written in C++ language and is available upon request on the 
homepage of the last author. 
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Figure S4. Screening by explicit solvent molecular dynamics. 2D representation of binding 
mode as well as MD time series of Hbonds of four scaffolds identified by the ALTA virtual 
screening approach. The two molecules in the top panels are discarded because their hydrogen 
bonds with the hinge region break apart within the first 10 ns. 
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Abstract: Drug discovery has seen the increasingly importance of structure-based virtual 
screening, in which molecular docking plays a key role. Other than developing a sophisticated 
physics-based scoring function to improve accuracy in prediction of binding poses, here we 
present a new flexible docking tool (called Mr. Dock) by taking advantage of Molecular 
Recognition in flexible Docking of small molecules to proteins, namely shape 
complementarity and hydrogen bonding. Mr. Dock shows a success rate of 94.1% on the 
Astex diversity set and of 97% on a new test set consisting of 100 kinase complexes. 
Prospectively, in a recent high-throughput virtual screening campaign against zeta-chain 
associated protein 70 (ZAP70), application of Mr. Dock leads to the discovery of several 
novel classes of inhibitors with IC50 in the low micromolar range, indicating its promising 
utility in structure-based virtual screening. 
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Introduction 
    Molecular docking, as computational simulation of a candidate ligand binding to a receptor, 
is used to predict the binding poses of small-molecule drug candidates into their protein 
targets of pharmaceutical relevance. It has emerged as an efficient tool in drug discovery, 
from hit identification to lead optimization and beyond.1,2 Flexible docking, in most cases so 
far, is limited to a chosen set of covalent bonds that can freely rotate in search of a native 
pose, while keeping the receptor, bond lengths and angles fixed.3-7 To allow for more degrees 
of freedom e.g. flexible receptor8 is not only computationally very expensive, but also could 
lead to dramatically increased false positives.  
    Molecular docking consists of essentially a scoring function and a random search 
algorithm. The scoring function, used to prioritize the poses in the process of random search, 
is core of molecular docking. It is typically in a form of energy function that aims to predict 
the binding free energy of a small molecule to the receptor. In the framework of empiric force 
fields, the binding free energy consists of van der Waals interaction energy, Coulombic 
interaction energy in vacuo, desolvation energy, conformational strain of small molecules, 
entropic loss of both small molecules and receptors, entropic gain by releasing constrained 
water molecules into the bulk, and so on. In order to improve the accuracy in prediction of the 
binding poses and also quite often the binding free energies, scoring functions in docking 
tools3-6 are thus trying to account for all the factors mentioned above, especially the 
mysterious role of water molecules5-6 in a physics-based approach.  
    The random search algorithm in early history is simulated annealing approach,3 with the 
risk of being trapped in local minima. Nowadays, docking tools4-7 typically adopt the 
evolution approach with a local optimization step during each generation. The random search 
algorithm has been extensively explored in computer science and protocols of optimized 
search can be easily found elsewhere. Finally, programming embodies a docking tool. The 
embodiment depends largely on the coding techniques, so that a docking tool should always 
be evaluated based on its performance in the field, instead of referring to its scoring function 
only. 
    Recently, Trott and Olson presented a docking tool called AutoDock Vina,7 based on a 
scoring function as more “machine learning” than directly physics-based in its nature. 
AutoDock Vina7 outstandingly outperforms the physics-based AutoDock 44, indicating 
“superficially physics-based scoring functions do not necessarily perform better”.7 From the 
perspective of molecular recognition, molecular docking is quite intuitive that small 
molecules bind to the receptors firstly in a shape complementary way and then are fixed by 
anchors of hydrogen bonds.  
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    Here, we report on a user-friendly and accurate docking tool (called Mr. Dock) that takes 
advantage of Molecular Recognition in flexible Docking. Mr. Dock was validated on the 
Astex diversity set9 with a success rate of 94.1% using biased geometry, and on the Kinase 
100 set10 with a rate of 97% using unbiased geometry. Prospectively, in a recent high-
throughput virtual screening campaign against zeta-chain associated protein 70 (ZAP70), 
which plays a crucial role in B- and T-cell activation,11-12 application of Mr. Dock leads to the 
discovery of several novel chemotypes with IC50 in the low micromolar range, indicating its 
promising utility in structure-based virtual screening. 
Methods 
    Scoring Function. The following scoring function is implemented in Mr. Dock: 
         Score = 0.18Vdw + 0.6Hb + 0.018Coul + 0.36Ninter-clash + 0.24Nintra-clash   (1) 
         Hb = wd*wa*(r – 2.8)                                                                                            (2) 
wherein, Vdw is the van der Waals interaction energy calculated by the corresponding 
equation in the CHARMM force field13; Hb is the hydrogen bonding energy calculated by 
equation 2; Coul is the Coulombic interaction energy by a distance dependent dielectric of r, 
and the first three terms were calculated among non inter-clash ligand atoms. Inter-clash is 
defined if interaction energy of the ligand atom with the protein is greater than 0.36 kcal/mol. 
Ninter-clash is the number of ligand atoms having clash with the protein; Nintra-clash is the number 
of pairs of ligand heavy atoms having intra-molecular clash, which is determined by a 
minimum pairwise distance of 3 Å or the shorter distance in the initial ligand conformation to 
allow for intra-molecular hydrogen bonds. wd and wa is the hydrogen bonding weight of 
donors and acceptors,10 r in equation 2 is the distance between the donor hydrogen atom and 
the acceptor, and HB equals 0 if r < 1.6 Å or r > 2.8 Å.  
    The van der Waals coefficient is directly derived from the previous scoring function 
incorporating hydrogen bonding penalty10, and the hydrogen bonding coefficient is taken 
from estimate of the net gain by formation of one hydrogen bond, around 0.6 kcal/mol. It has 
been observed that small coefficients of clash facilitate the simulated annealing search but 
smaller values deteriorate the poses, thus the coefficients of clash are determined according to 
the search performance. Partial charges were assigned only to donor hydrogen atoms and 
acceptors, with the aim to optimize the geometry of local polar interactions. The van der 
Waals attraction of carboxylic oxygen atom is set to zero in order to prevent from burial 
deeply inside the protein. 
    To speed up, energy of each ligand atom type (derived from the CHARMM general force 
field14 by merging similar ones, Table 1) in the binding site was calculated and stored in a 
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grid-based manner. The grid maps are calculated internally like in AutoDock Vina7, with a 
fine grid space of 0.2 Å. The energy of each atom type is then retrieved to get the binding 
energy during conformational search. 
Table 1. Defined ligand atom types. 
Element H C N O & F P & I Br & S Cl 
εmin (kcal/mol) -0.046 -0.062 -0.20 -0.12 -0.55 -0.42 -0.32 
rmin (Å) 0.55 2.00 1.60 1.50 2.18 2.07 1.93 
    Hybridized Search Algorithm. The genetic algorithm is adopted, with the first generation 
obtained from simulated annealing search. At the beginning of each simulated annealing 
search, the input ligand conformation, including its position, orientation and torsions, is 
randomly changed, so that each search starts with a different ligand conformation. 
    Implementation. Mr. Dock was coded in C++ language, with a simplified input interface: 
size of the binding site, number of runs, root mean square deviation (RMSD) cutoff for 
clustering of poses, and a ligand list for continuous docking without re-calculating the grid 
maps. Unlike AutoDock7-8, Mr. Dock directly reads small molecules in a TRIPOS mol2 
format, thus eliminating the step of preprocessing small molecules by a different tool. 
However, the protein still needs to be prepared by a third-party tool to add hydrogen atoms, 
and assign both partial charges and CHARMM/m atom types. In all, the time spent on 
developing Mr. Dock together with the following validation on a set of about 200 protein-
ligand complexes was within one month. 
Docking Setup 
    Training Set. The training set includes 10 complexes including kinases, β-secretase, HIV-
protease, influenza virus neuraminidase, dihydrofolate reductase and thrombin, which are of 
interest to the majority of medicinal chemists. The 2D structures of the complexed inhibitors 
are shown in Figure 1. Flexible docking of such inhibitors is generally regarded as tough 
cases,4 given the number of active rotatable bonds.  
    Test Set. The test set includes the Astex diversity set9 and a new test set consisting of 
kinases only10. The Astex diversity consists of 85 proteins of drug or agrochemical targets, 
with almost no global sequence similarity.9 Since our primary interest is on protein kinases 
that are involved in one third of current drug discovery programs15, we further include 100 
kinases (Figure 2), previously used to analyze hydrogen bonding penalty upon ligand 
binding10.  
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    Protein Preparation. All water molecules were removed and metal ions coordinating with 
ligand were kept. Hydrogen atoms were added according to the protonation states of chemical 
groups at pH 7, MPEOE partial charges16 and CHARMm atom types17 were assigned by the 
program WITNOTP. Alternatively, the protein structure can be prepared by the program 
VMD18 with both partial charges and CHARMM atom types13 assigned.  
    Docking. The binding site was determined as within 4 Å from any atom of the complexed 
ligand. The number of runs was set as 20 and RMSD cutoff as 1 Å. 
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Figure 1. 2D representations of small molecules in the training set including two kinase 
inhibitors (PDB code 3GC7 and 1OPJ), two β-secretase inhibitors (3PI5 and 2QMF), two 
HIV-protease inhibitors (1HVR and 1HVS), one influenza virus neuraminidase inhibitor 
(2QWE), one dihydrofolate reductase inhibitor (4DFR) and one thrombin inhibitor (1ETS). 
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Figure 2. Profile of the Kinase 100 set. 
Results and Discussions 
    Shape Complimentarity. Shape complimentarity between ligands and receptors is an 
essential aspect of molecular recognition,19 and there are numerous cases where natural 
substrates bind to the specific shape of the binding site.20-21 At the very beginning, the scoring 
function consists of only van der Waals interaction energy. Surprisingly, we found that native 
poses in the crystal structures for the training set still can be reproduced although with low 
convergence i.e. that the probability of reproducing the native pose from multiple runs is low. 
It gives moderate convergence for two kinase inhibitors (3GC7 and 1OPJ) and one HIV 
protease inhibitor (1HVR). The complexed inhibitor in PDB entry 3GC7 is quite rigid in a 
unique shape, thus binding to the ATP site of the kinase in a specific way although the 
binding site itself is an open cleft without imposing steric constraints on the ligand shape. 
While for the inhibitor complexed in 1OPJ (7 rotatable bonds) or 1HVR (10 rotatable bonds), 
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the inhibitor itself is quite flexible, but the specific shape of the binding site restricts the 
conformational space that the ligand can adopt upon binding. In these three cases, the search 
guided by van der Waals interaction only is able to locate the native pose with a moderate 
convergence, due to shape complimentarity that requires no clash between ligands and 
receptors. 
 
 
Figure 3. Best predicted pose (magenta) superimposed on the native pose (cyan) in the 
training set. 
    Hydrogen Bonding. The dissociation energy of a hydrogen bond covers more than two 
orders of magnitude from about 0.2 to 40 kcal/mol,22 and moderate hydrogen bonds in the 
biological system resembling those between water molecules or in carbohydrates are 
associated with energies in the range from 4 to 15 kcal/mol.22-23 Therefore, hydrogen bonding 
is another important aspect of molecular recognition. In the scoring function of AutoDock,3 
an energy function in a form similar to the van der Waals equation is used for hydrogen 
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bonds. Later on in AutoDock Vina,7 a linear distance dependent function is adopted. Here, we 
keep the linear function form, but with introducing hydrogen bonding weights based on the 
consideration that strength of a hydrogen bond relies on the specific donor and acceptor pair. 
The concept of hydrogen bonding weights has been practiced in our early work,10 and in the 
current application we expanded the Hbond atom types to better distinguish donors or 
acceptors in different chemical environments (data not shown). The values of the hydrogen 
bonding weights were derived from our chemical intuitions and experiences in structure-
based virtual screening,10, 24-25 and further optimized in a trial and error procedure with the 
aim to reproduce the native poses. The metal ions are treated as hydrogen bonding donors like 
in X-score.26  
Table 2. Docking performance in the training set. 
Protein PDB 
code 
Rotatable 
bonds 
RMSD 
(Å)a,b 
fRMSD≤2.0Åa,c 
(%) 
Time per run 
(minutes) 
3GC7 4 0.63 100 0.40 Kinase 
1OPJ 7 0.38 85 0.57 
3PI5 8 0.45 25 0.55 β-secretase 
2QMF 14 0.52 30 0.70 
1HVR 10 0.37 95 0.63 HIV protease 
1HVS 21 1.19 5 1.33 
Influenza virus 
neuraminidase 
2QWE 9 0.36 85 0.40 
Dihydrofolate 
reductase 
4DFR 11 1.35 35 0.47 
Thrombin 1ETS 9 0.58 10 0.58 
aRMSD calculated by ligand heavy atoms with respect to its native pose. bby the best pose. 
cPercentage of poses with RMSD within 2 Å. The RMSD cutoff of 2 Å is often used as a 
criterion of the correct bound structure prediction. 
    During simulated annealing search, small clash coefficients allow to quickly locate non-
clash conformations by lowering the barriers; while hydrogen bonding interaction traps the 
ligand in a conformation in favor of good hydrogen bonding pattern. Hydrogen bonds has 
long been recognized for its role in providing binding specificity, and it is indeed more 
efficient to incorporate hydrogen bonding interaction by directing the search towards the 
native pose. As a result, it leads to a better convergence with significantly improved accuracy 
(Table 2 and Figure 3), even lack of a local optimization step in the evolution search. Without 
hydrogen bonding weights, the search could be trapped into unrealistic conformations which 
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simply favor more hydrogen bonds even rather weak, decreasing search efficiency and 
sometimes even failing to reproduce the native pose. 
Table 3. Docking performance on Astex diversity set and Kinase 100 set.a  
 fRMSD≤2.0Åb (%) fRMSD≤2.0Åc (%) Time per rund (minutes) 
Astex diversity set9 94.1 ± 2.0e 82.4 ± 0.0e 0.28 
Kinase 100 set10 97 91 0.40 
aFor Astex diversity set, the geometry of native poses was used as input; while for Kinase 100 
set the unbiased geometry was used by minimizing the native poses with the CHARMm force 
field in the absence of the proteins. In both cases, the native poses were reoriented manually 
to remove the memory of binding. bby the best pose among 20 runs. cby the first-ranked pose 
among 20 runs. dexcluding the time of processing proteins which can be calculated just once 
in a high-throughput screening. estandard deviation based on three replicates with each 
consisting of 20 runs. 
    Validation on Test Sets. Compared with the success rate of 86.5% by GOLD on the Astex 
diversity set,9 Mr. Dock gives a rate of 94.1% by the best pose and 82.4% by the first-ranked 
pose (Table 3 and Figure 4). 
Astex diversity set Kinase 100 set
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Figure 4. Distribution of RMSD of the best pose among 20 runs relative to the native pose in 
the crystal structure. 
    In re-docking of the Astex diversity set, both the position and orientation of the native 
poses were changed randomly in order to remove the memory of binding, however, the 
geometry was kept unchanged. It has been pointed out that conformation of a bound ligand 
could be different from its unbound state and even small changes in bond angles could lead to 
failure of re-docking.27 Keeping this in mind, we minimized the native poses in the absence of 
proteins to get unbiased geometry for the Kinase 100 set before re-docking. Notably, Mr. 
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Dock gives a success rate of 97% by the best pose and 91% by the first-ranked pose (Table 3 
and Figure 4).  
    Not surprisingly, Mr. Dock performs better on the Kinase 100 set, and especially on the 
type II kinase inhibitors even they typically possess more rotatable bonds than type I 
inhibitors. Kinase inhibitors are in general hinge binders which form two or three hydrogen 
bonds with hinge of the ATP site. With the flip of the activation loop when kinase is in its 
inactive state, the type II inhibitors take advantage of the exposed allosteric site and form two 
or three additional hydrogen bonds with the protein.15 Hydrogen bonding together with shape 
complementarity then can well position the kinase inhibitors into the binding site. Indeed, use 
of hydrogen bonds has become one of our routine procedures in discovery of novel kinase 
inhibitors.10, 24-25 
    The failure on a few cases from the Astex diversity set (e.g. 1HVY and 1XM6) originates 
from the absence of a robust desolvation term in the scoring function. In the absence of 
crystal waters, ligands tend to be in a close contact with the proteins to gain favorable van der 
Waals interaction, which should be prevented otherwise if a desolvation penalty is present. It 
has been shown that presence of crystal waters improves re-docking accuracy.28 Aside from 
the mysterious magic of water molecules, it is not surprising at all since presence of crystal 
waters significantly reduces the conformational space of a bound ligand by imposing steric 
constraints, turning the binding site into a template of the ligand’s shape.9 
    The average computational time per run on a commodity computer (a single Intel 2.8 GHz 
CPU) is 0.28 minutes for the Astex diversity set, and 0.40 minutes for the Kinase 100 set. The 
memory usage varies from about 40 to 90 MB, depending on the size of the binding site. 
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Figure 5. Correlation between the predicted and experimental binding affinities for the 
Kinase 100 set. Inset: Astex diversity set.  
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    Scoring Function. The scoring function 1 was empirically derived based on our 
experiences in discovery of kinase inhibitors,10, 24-25 without further fitting. The kinase 
binding site is predominantly hydrophobic,29 and the electrostatic contribution as a sum of 
Coulombic interaction in vacuo and desolvation is marginal.10, 29 In Mr. Dock, partial charges 
were assigned only to donor hydrogen and acceptor atoms with the purpose of optimizing 
local polar interactions, and the electrostatic coefficient is only 10% van der Waals 
coefficient. The electrostatic contribution in Mr. Dock is thus consistent with our observation 
on kinase inhibitors binding. Notably, Mr. Dock achieves a root mean square error of 1.83 
kcal/mol for the Kinase 100 set (Figure 5). In contrast, Mr. Dock tends to underestimate the 
binding affinity in the Astex diversity set in the case where hydrophilic interaction is 
dominant.  
    Unlike other docking tools3-7, prediction of binding affinities is no longer the pursuit of Mr. 
Dock. In order to improve computational efficiency, a docking tool often introduces many 
approximations and sometimes “machine-learning” elements into the scoring function.7 We 
suggest that a more sophisticated energy function should be used to predict the binding 
affinity upon energy minimization following docking, and use a docking tool only to generate 
binding poses, as shown in our previous practices.10, 24-25 In this sense, we expect only 
moderate convergence of docking, so that a diversity set of poses can be available for 
subsequent evaluation by a more accurate energy function. 
    Prospective Application of Mr. Dock. Limited prospective applications do not necessarily 
indicate the validity of a tool or method; however, it is our only interest to develop Mr. Dock 
for its application in the field. Firstly, rational binding poses of three series of kinase 
inhibitors10, 24-25 including one type II inhibitor24 (the predicted binding poses of two 
nanomolar inhibitors10, 25 have been confirmed by X-ray), previously discovered by 
AutoDock 44, were successfully reproduced by Mr. Dock. Secondly, we applied Mr. Dock in 
a recent high-throughput virtual screening of novel inhibitors for zeta-chain associated protein 
70 (ZAP70), for which a cell-permeable and highly specific inhibitor has not yet been 
reported.11-12 Several novel chemotypes with IC50 in the low micromolar range were 
discovered (H. Zhao, in preparation), indicating its promising utility in structure-based virtual 
screening. 
Conclusions  
    In summary, we present a flexible docking tool that takes advantage of molecular 
recognition in docking of small molecules to proteins, with comparable or slightly better 
performance. However, hydrogen bonding weights, partial charges, and details in the search 
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algorithm are not in the scope of discussion for the following reasons: 1) It follows our simple 
chemical and physical intuitions, as exemplified previously.10 2) In the optimization of 
docking performance, we found that generally a success rate of more than 80% can be 
achieved as long as hydrogen bonding interaction was included, indicating a wide range for 
choice of different combinations of hydrogen bonding weights. We expect that this 
information would be enough for developers. 3) We want to keep it in a concise and clear way 
with emphasis on the docking performance, which is of sole interest to the majority of 
practitioners in the field of medicinal chemistry. 
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ABSTRACT: We have discovered six novel classes of ZAP70 inhibitors by docking into a 
protein conformation generated by molecular dynamics. Molecular dynamics simulation of 
ZAP70 with a potent JAK2 inhibitor was carried out to induce a fit of the gatekeeper residue 
Met414 and the back pocket. Two compounds with IC50 of about 10 µM were predicted to 
occupy the back pocket, and the well-established optimization scheme on the moieties in the 
back pocket suggests that potent ZAP70 inhibitors might be obtained by the addition of a 
hydroxyl group. The finding of a novel 110 nM JAK2 inhibitor on the other hand emphasizes 
the importance of including kinases sensitive to chemical inhibition in the screening panel. 
 
KEYWORDS: ZAP70, virtual screening, molecular dynamics, autoimmune disease 
 
Page | 76                                                                         6. Discovery of Novel ZAP70 Inhibitors 
 
 
Zeta-associated protein 70 kDa (ZAP70), a member of the Syk family and non-receptor 
protein tyrosine kinases, mainly expressed on T cells and natural killer cells, plays a crucial 
role in immune response and is implicated in inflammatory and autoimmune disease.1-2 
ZAP70 is an attractive therapeutic target for various allergic and autoimmune disorders as 
well as organ transplant medication. Although four series of small-molecule ZAP70 inhibitors 
have been discovered (Figure 1),3-7 a cell-permeable and highly specific ZAP70 inhibitor has 
not yet been reported.2 Most kinase inhibitors promiscuously inhibit multiple kinases, but a 
recent comprehensive selectivity profiling of 178 commercial available kinase inhibitors on a 
panel of 300 recombinant protein kinases revealed that ZAP70 is less druggable by chemical 
inhibition,8 which is further confirmed by a second profiling of 72 inhibitors with 442 
kinases.9   
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Figure 1. Four series of nanomolar ZAP70 inhibitors. 
Previously we have discovered three novel classes of tyrosine kinase inhibitors,10-12 which 
bind into the ATP site occupying the hydrophobic back pocket (PDB code 4G2F12 and 
4GK2). Optimization of the moieties in the back pocket quickly leads to potent and selective 
tyrosine kinase inhibitors12-13 although the two initial hits of different chemotype are weak 
binders (Figure 2).10, 12 More examples can be found elsewhere that targeting the back pocket 
is a rather efficient way to gain both potency and selectivity in kinase drug design.14  
The access of the back pocket is modulated by a so called gatekeeper residue. ZAP70 has a 
bulky gatekeeper residue Met414, which blocks the entry of the back pocket and thus makes it 
inaccessible by small molecules as shown in two available crystal structures so far (PDB code 
1U594 and 2OZO15). However, analysis of complex structures of kinases with a bulky Met 
gatekeeper residue in the Protein Data Bank reveals that the back pocket of some kinases such 
as JAK216 and JNK317 still can be accessed by few potent small-molecule inhibitors. 
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Although belonging to a different subfamily and sharing low overall sequence identity with 
ZAP70, JAK2 (PDB code 3KCK16) shows a high geometric similarity in the ATP site with 
ZAP70 (PDB code 1U594). Manual placement of the complexed JAK2 inhibitor16 (Figure 3) 
into the ZAP70 ATP site by aligning the two crystal structures encounters slight van der 
Waals clashes. Following the protocol previously presented,18 molecular dynamics simulation 
of ZAP70 complexed with this putative ligand was carried out to induce a fit of the 
gatekeeper residue Met414 and the back pocket, so that the slight clashes can be 
accommodated by reorganization of the protein to allow exploration of the back pocket in 
virtual screening. One single snapshot called as MD-IF (molecular dynamics induced fit) 
structure was then selected for subsequent high throughput virtual screening, based on 
evaluation of hydrogen bonds formed between the putative ligand and ZAP70. 
 
Figure 2. Hit to lead by optimization of the moieties (colored in blue) in the back pocket, and 
crystal structures of E02 (4GK2) and E04 (4G2F) bound to the kinase domain of EphA3. 
Dashed lines represent intermolecular hydrogen bonds. 
  The ZINC-all now library19 (version of 2011) was first filtered to generate a kinase focused 
library by physicochemical properties: 1) Mw less than 380 g/mol; 2) number of rotatable 
bonds less than 8; 3) at least one donor and two acceptors; 4) number of rings from 3 to 5. 
The initial library of nearly 9 million compounds was reduced to a focused library of about 
750,000, which was then docked into the MD-IF structure by a recently developed fast 
docking tool Mr. Dock (Mr. Dock: Molecular Recognition in Flexible Docking of Small 
Molecules into Proteins, Zhao and Caflisch, unpublished). Mr. Dock adopts a combination of 
simulated annealing and genetic algorithm optimization of position, orientation, and rotatable 
bonds of the ligand, with a successful rate of 94.1% on the Astex diversity set20 and of 97% 
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on the 100 kinase complexes.11 The docking poses were further minimized in the rigid protein 
by CHARMM21-22 with the CHARMm22 force field.23 The poses were then subject to three 
filters: van der Waals efficiency of -0.1 kcal/g,18 hydrogen bonding penalty11 of 2, and 
hydrogen bonds to the hinge, to gain computational efficiency by removing unrealistic poses 
before rescoring by a sophisticated energy function. Afterwards, the passed compounds were 
ranked according to a previously reported scoring function,11 which has a proved track record 
in discovery of novel classes of kinase inhibitors with activity ranging from low micromolar 
to nanomolar.11-12, 18 Finally, 32 compounds were selected and purchased for bioassay. The 
process of virtual screening is briefly illustrated in Figure 3. 
Induce a fit of the protein by
ZINC all-now
9 Million
Focused library
~750,000
Pharmacophore filter
32 Candidates
1. Docking by Mr. Dock
2. Post-docking scoring
10 hits of 6 scaffolds
Bioassay
Crystal structure of
ZAP70 (1U59)
N
N
H
N
OH
Cl
JAK2: 0.8 nM
 
Figure 3. Flow chart of virtual screening. 
The IC50 measurements on full-length ZAP70 were carried out at Reaction Biology Corp. 
with radioactive ATP at 1 µM concentration. Notably, 10 compounds of 6 novel scaffolds 
showed low micromolar inhibitory activity against ZAP70, with the most active being 8.5 
µM. Figure 4 shows the representative compound of each scaffold with IC50 values listed in 
Table 1. All the six compounds are predicted to form at least two hydrogen bonds with 
Ala417 of the hinge, a segment linking the N- and C-lobe of the kinase domain (Figure 5 and 
6). Compounds 01, 03 and 04 form an additional hydrogen bond with Glu415 of the hinge. 
Such hydrogen bonding pattern is a typical feature of hinge binders, mimicking ATP binding. 
Compounds 01 to 04 do not occupy the hydrophobic back pocket, and the same binding 
modes can be reproduced by docking into the original crystal structure (1U59). In contrast, 
compounds 05 and 06 utilize the back pocket, and thus cannot be docked into the crystal 
structure in a rational way. Although compound 05 and 06 have two different linkers, the 
head and tail moieties are essentially overlapped in the docked poses (left bottom, Figure 6). 
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Previously, we have shown that the addition of a hydroxyl group to the moiety in the back 
pocket leads to an increase in binding affinity by a factor of more than 50 (Figure 2).12-13 
Similar effect in one series of JAK2 inhibitors16 (one of which complexed in 3KCK was used 
to induce a fit of ZAP70) can also be inferred. As shown in Figure 6 (right bottom), the 
addition of a hydroxyl group would form two perfect buried hydrogen bonds with Phe480 of 
the DFG motif and the catalytically important Glu386. The addition of a carboxylic group to 
the water accessible phenyl ring would form a salt bridge with ZAP70 specific Lys424, which 
might change the selectivity profile towards ZAP70 and increase the solubility. The rather 
straightforward hit optimization is the motivation of inducing a fit of the protein, so that the 
back pocket can be explored and the well-established optimization scheme12-13 can be directly 
implemented. 
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Figure 4. Selected novel ZAP70 inhibitors. 
 
Table 1. Inhibitory Activity (IC50 in µM) of Discovered Active Compounds.a 
Compd ZAP70 SYK JAK2 
01 28.8  >200 NDb 
02 20.9  168 ND 
03 61.9  11.7 0.11 
04 8.48 26.2 11.2 
05 13.7 57.4 5.86 
06c 21.9 ND 15.1 
aIC50 was determined by enzymatic assay of 10-dose response with radioactive ATP at 1 µM 
concentration carried out at Reaction Biology Corp. bNot determined. cBy substructure search 
on the vendor website. 
The phenomenon of induced fit where the binding site alters upon binding to become very 
specific for the given ligand limits the use of the crystal structure in virtual screening. To 
circumvent this issue, soft docking has been proposed and flexible-residue docking that 
Undisclosed 
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allows certain flexibility of the protein has already been implemented in AutoDock 4.24 
Flexible-residue docking increased the success rate of cross docking at the cost of 
computational efficiency, but both flexible-docking and particularly soft docking would lead 
to a dramatic increase in false positives. Alternatively, molecular dynamics simulation of the 
protein was used to obtain an ensemble of conformations, each of which was then used for 
docking in parallel.25-26 The disadvantage of this scheme is the computational inefficiency, 
and the difficulty in selecting the conformations since ligand binding is a long-range 
conformational selection complemented by a more localized ligand-induced conformational 
shift27, which means snapshots from simulations of an apo structure may not be suitable for 
docking due to collapse in the binding site. Here, the molecular dynamics induced fit 
scheme18 that includes a desirable ligand (usually a potent inhibitor) in the binding site is a 
direct and fast way to obtain desired conformations for docking. Since harmonic constraints 
are used and thus the obtained conformation resembles the original crystal structure except 
where one wants to be induced, it at least guarantees the success that can be obtained on the 
original crystal structure such as the discovery of compounds 01 to 04.  
 
Figure 5. Predicted binding modes of compounds 01 to 04 into the MD-IF structure. Dashed 
lines represent intermolecular hydrogen bonds. 
Syk family inhibitors typically selectively inhibit spleen tyrosine kinase (Syk) other than 
ZAP70, although they are closely related.8-9, 28 Interestingly, compounds 01, 02 and 05 
selectively inhibit ZAP70 with a selectivity index of around 5 for Syk. They might serve as 
starting points for hit optimization into potent and selective ZAP70 inhibitors, given their low 
molecular weight. Since JAK2 shares a high similarity in the ATP site with ZAP70, 
compounds 03 to 06 were also tested on JAK2. Surprisingly, compound 03 exhibits a 
Undisclosed 
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moderate potency of 110 nM on JAK2 with a selectivity index of 562 for ZAP70, indicating 
that selectivity might be a much more complicated issue than expected. As previously 
suggested,8 this finding indeed emphasizes the importance that the screening panel of kinases 
should include kinases sensitive to chemical inhibition and yet showing high similarity in the 
ligand site with the primary target, in order to increase the success rate. 
 
Figure 6. Predicted binding modes of compounds 05 and 06 in the MD-IF structure, and 
suggested hit optimization for compound 05. Dashed lines represent intermolecular hydrogen 
bonds. 
In summary, we have discovered six novel classes of ZAP70 inhibitors by docking into a 
protein conformation generated by molecular dynamics, with two compounds are predicted to 
occupy the hydrophobic back pocket. The well-established optimization scheme for the 
moieties in the back pocket might be adopted directly to obtain potent ZAP70 inhibitors. The 
finding of a novel 110 nM JAK2 inhibitor suggests the importance of including sensitive 
kinases in the screening panel. 
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Identification of Novel EphB4 Kinase Inhibitors via Structure-
Based Virtual screening on a Modeled DFG-out Conformation 
 
 
ABSTRACT: Discovery of type II kinase inhibitors that target a DFG-out conformation stays 
on focus, driven by selectivity and intellectual property novelty. Unavailability of 
experimental DFG-out kinase structures greatly limits the structure-based virtual screening. 
Here, we present the discovery of a novel scaffold via virtual screening based on a modeled 
DFG-out conformation of EphB4 kinase, with the most active compound showing an IC50 of 
5.4 μM. Enzymatic assay suggests this scaffold would be able to adopt a type I binding mode, 
with slightly more favorable binding to an inactive conformation. 
 
KEYWORDS: Virtual screening, type II kinase inhibitors, EphB4, homology modeling 
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The human genome consists of 518 kinases, which have been demonstrated to play essential 
roles in virtually every aspect of cellular physiology.1 Dysregulation of kinase activity has 
been implicated in pathological conditions ranging from neuronal disorders to cellular 
transformation in leukemia.2 The erythropoietin-producing human hepatocellular carcinoma 
receptor (Eph), the largest known family of receptor tyrosine kinases, has been implicated in 
sprouting angiogenesis and blood vessel remodeling during vascular development.3 
Furthermore, over-expression of several of the 14 Eph receptors particularly regarding EphB4 
has been linked to tumors and the associated vasculature, suggesting a critical role in tumor 
related angiogenesis. 
The absolute majority of small-molecule kinase inhibitors developed so far target the ATP 
binding site of the kinase in its active state (DFG-in), as historically most inhibitors have been 
discovered using biochemical screens of highly active, activation loop-phosphorylated 
recombinant kinase catalytic domains.4 However, the first small-molecule kinase inhibitor to 
reach the market is Imatinib (Gleevec, Novartis), a type II compound that recognizes an 
inactive state of the kinase characterized by a closed conformation of the activation loop 
(DFG-out). The flip of DFG-motif, a conserved triad Asp-Phe-Gly at the beginning of the 
activation loop, induces remarkable changes in the ATP binding site and exposes an 
additional hydrophobic pocket that is less conserved in sequence.5 Many kinase inhibitors 
have failed in preclinical or clinical development due to lack of selectivity that induces 
intolerable side effects, largely because the ATP binding site is highly conserved in sequence 
and conformation.6 The emergence of type II inhibitors creates new opportunities by targeting 
the allosteric pocket in a DFG-out conformation, offering selectivity and intellectual property 
novelty.7  
Structure-based virtual screening based on a DFG-out conformation is often limited by the 
unavailability of experimental structures. As a result, most known type II inhibitors to date 
have been developed via QSAR-guided modifications of ATP-site ligands.4 Several 
computational approaches have been proposed to convert a DFG-in into an out kinase 
conformation, such as DOLPHIN by deleting about six residues of the activation loop starting 
with the DFG motif.8 More recently, a protein remodeling program has been used to model a 
DFG-out conformation by using the DFG-in as a template structure.9 However, such methods 
stay on the stage of retrospective validation, and the prospective virtual screening validation 
needs to be confirmed. 
The flip of the DFG-motif is often accompanied by the reorganization of the N-lobe, 
especially an outward rotation of the αC-helix,10 which certainly imposes difficulty in 
modeling DFG-out conformations by using DFG-in structures as templates. However, the 
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story is not always so complicated with the exception of Abelson tyrosine kinase (Abl), which 
N-lobe in the DFG-out conformation is essential identical to that in the DFG-in 
conformation.11 Assuming the same scenario for EphB4, a DFG-out EphB4 conformation was 
prepared via homology modeling using the program Modeller12 based on the co-templates of 
DFG-out Abl (PDB entry 1OPJ) and activation loop-deleted active EphB4 (2VWX). The 
availability of both DFG-in (2QO2) and out (3DZQ) crystal structures of EphA3 later on 
allows us to evaluate this assumption for Eph family. The overall conformation of the kinase 
domain, including the interlobe orientation and the conformation of helix αC, is essentially 
identical in the in and out structures of EphA3, reflected by a small RMSD value of 0.19 Å on 
211 Cα atom pairs, except the highly flexible glycine-rich loop (G-loop), which can adopt 
various conformations depending on the conformational state of a protein kinase and the 
presence of a ligand6 (Figure 1). The EphB4 kinase domain shares a sequence identity of 74% 
with the EphA3, indicating this assumption might hold for EphB4. 
 
Figure 1. Superimposition of DFG-out (red, PDB entry 3DZQ) and DFG-in (blue, 2QO2) 
crystal structures of EphA3.  
To refine the type II binding site, compound 113 (Figure 2) was manually placed into the 
binding site in a way as expected for type II inhibitors binding.4 The complex was then 
subject to an explicit solvent molecular dynamics simulation using NAMD14 with the all-atom 
CHARMM PARAM27 force field15 and the TIP3P model of water16, by applying harmonic 
constraints on Cα atoms except the activation loop based on the above assumption. The 
simulation runs for 10 ns after 1 ns equilibrium with water molecules. One snapshot was 
selected by visual inspection of the 10 ns trajectory guided by the interaction energy between 
compound 1 and the protein. The selected snapshot was further minimized with CHARMM17 
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and the CHARMm22 force filed18, and then compound 1 together with all the water 
molecules were removed to generate a DFG-out conformation for high-throughput docking. 
Type II binding modes of the two known type II inhibitors19 including Sorafenib (Figure 2) 
can be well reproduced based on the refined conformation. 
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Figure 2. Previously known type II EphB4 inhibitors.13, 19 
Table 1. Discovered novel EphB4 kinase inhibitors. 
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5  
Compd 2 3 4 5 IC50 (µM)a 
2 CH3 H H H 5.4 
3 H CH3 CH3 H 8.5 
4 H H H H 17.4 
5 H H CH3 H 15.8 
6 CH3CH2 H H H 22.8 
aAll IC50 values are means of at least two dose-response determinations by Invitrogen Zlyte 
Tyr 1 kinase assay kit. 
A compound library of about 0.8 million, filtered out from ZINC20 by at least 3 rings and 4 
N&O atoms, was docked into the prepared DFG-out conformation using Version 4 of 
AutoDock21. The procedures to pre-process compounds and docking parameters can be found 
elsewhere.22 The docked poses were further minimized in the rigid protein with CHARMM17 
and the CHARMm22 force filed18. The poses were firstly filtered by three hydrogen bonds 
(one hydrogen bond with the hinge Met696 and two additional hydrogen bonds with Glu664 
and Asp758, respectively. See Figure 3), and then ranked by the following scoring function: 
)1(strainsolvcoulvdW EGEEG Δ+Δ+Δ+Δ=Δ  
wherein, ΔEvdW is the intermolecular van der Waals energy, ΔEcoul is the intermolecular 
Coulombic energy in vacuo, ΔEstrain is the strain energy of ligand upon binding, and ΔGsol is 
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the change in solvation energy of ligand and protein upon binding. The details to compute the 
above scoring function is described elsewhere.22 
 
Figure 3. Predicted binding mode of compound 3 in the modeled DFG-out conformation of 
EphB4. Hydrogen bonds are shown by blue dashed lines. 
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Figure 4. Structural analog the hypothetic type I binding mode of the discovered scaffold to 
that of Dasatinib. Proposed binding mode of Dasatinib to EphB4 was based on the crystal 
structure of Abl complexed with Dasatinib (PDB entry 2GQG). 
A novel scaffold was discovered with the most active compound having an IC50 of 5.4 μM 
on the recombinant active EphB4 protein by Invitrogen Zlyte Tyr 1 kinase assay kit as 
previously described22 (Table 1). As shown in Figure 3, compound 3 forms three important 
hydrogen bonds quite often seen on known type II inhibitors: one interacts with the hinge 
Met696 backbone amide nitrogen, and the other two with the DFG motif Asp758 amide 
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nitrogen and the catalytically important Glu664 carboxylic oxygen. Normally, the type II 
inhibitors are more potent on inactive kinase by an order of magnitude than on active,23 
presumably because the DFG-out conformation is more populated when the kinase is inactive. 
A displacement assay by Invitrogen Lantha actually shows that all the discovered compounds 
are about 3 times more potent on inactive EphB4 kinase although the compounds unfavorably 
interfere with the fluorescence assay, while the type I inhibitor Dasatinib shows slightly 
decreased activity on inactive EphB4 (data not shown). Therefore, the discovered scaffold did 
not show the typical behavior of a type II binding mode. Previously, we postulated that it 
might adopt a type I binding mode targeting the active conformation, as indicated by 
structural analog to the type I inhibitor Dasatinib (Figure 4). However, three years later I now 
intend to postulate that it might target a DFG-in, αC-Helix out inactive conformation. 
It is estimated that one third of drug discovery programs target protein kinases,24 and such 
assessment drives an eager search for truly novel scaffolds given the fact that many kinase 
inhibitors fail in the clinical developments. Given its novelty and low micromolar activity, we 
think compound 2 deserves future elaborations. 
 
7. Deterministic or Serendipity?                                                                                     Page | 91 
 
References 
1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. Science 2002, 298, 1912. 
2. Hunter, T. Harvey Lect 1998, 94, 81. 
3. Adams, R. H. Semin Cell Dev Biol 2002, 13, 55. 
4. Liu, Y.; Gray, N. S. Nat Chem Biol 2006, 2, 358. 
5. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Science 2004, 303, 1800. 
6. Liao, J. J. J Med Chem 2007, 50, 409. 
7. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. J Med Chem 2010, 53, 2681. 
8. Kufareva, I.; Abagyan, R. J Med Chem 2008, 51, 7921. 
9. Xu, M.; Yu, L.; Wan, B.; Huang, Q. PLoS One 2011, 6, e22644. 
10. Huse, M.; Kuriyan, J. Cell 2002, 109, 275. 
11. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; 
Kuriyan, J. Cancer Res 2002, 62, 4236. 
12. Sali, A.; Blundell, T. L. J Mol Biol 1993, 234, 779. 
13. Miyazaki, Y.; Nakano, M.; Sato, H.; Truesdale, A. T.; Stuart, J. D.; Nartey, E. N.; Hightower, K. E.; Kane-
Carson, L. Bioorg Med Chem Lett 2007, 17, 250. 
14. Kale, L.; Skeel, R.; Bhandarkar, M.; Brunner, R.; Gursoy, A.; Krawetz, N.; Phillips, J.; Shinozaki, A.; 
Varadarajan, K.; Schulten, K. J Comput Phys 1999, 151, 283. 
15. MacKerell, A. D.; Bashford, D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, 
J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; 
Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; 
Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. J Phys Chem B 1998, 102, 3586. 
16. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. J Chem Phys 1983, 79, 926. 
17. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. J Comput Chem 
1983, 4, 187. 
18. Momany, F. A.; Rone, R. J Comput Chem 1992, 13, 888. 
19. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; 
Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; 
Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. Nat Biotechnol 
2008, 26, 127. 
20. Irwin, J. J.; Shoichet, B. K. J Chem Inf Model 2005, 45, 177. 
21. Goodsell, D. S.; Olson, A. J. Proteins 1990, 8, 195. 
22. Zhao, H.; Huang, D. PLoS One 2011, 6, e19923. 
23. Lebakken, C. S.; Riddle, S. M.; Singh, U.; Frazee, W. J.; Eliason, H. C.; Gao, Y.; Reichling, L. J.; Marks, B. 
D.; Vogel, K. W. J Biomol Screen 2009, 14, 924. 
24. Weinmann, H.; Metternich, R. Chembiochem 2005, 6, 455. 
Page | 92                                                                                        
 
Conclusions and Outlook 
 
    In summary, we developed a preliminary virtual screening platform consisting of a new 
flexible docking tool and a new scoring function having improved accuracy. We further 
optimized the in silico fragment-based approach by introducing a novel fragmentation 
scheme. To circumvent the induce-fit issue arising in docking, we developed a molecular 
dynamics-based method allowing the exploration of larger areas of chemical space when 
docking into a single protein structure. Applications of this platform led to several novel 
classes of kinase inhibitors. Predicted binding modes were validated by X-ray 
crystallography. Hit-to-lead optimization guided by computational modeling led to potent and 
selective kinase inhibitors that hold promise in their future elaboration as clinical drugs. 
    One limitation of the current method is that empirical force field-based docking/scoring 
takes place with a static protein structure that neglects both receptor flexibility and potentially 
relevant water molecules. Future work should focus on the validation/optimization of 
parameters for small molecules, which are the basis for force field-based approach. Further, it 
would be beneficial to use molecular dynamics (MD) simulations to deepen the understanding 
of protein-ligand interaction by explicitly involving both receptor flexibility and water 
molecules. The information derived from MD sampling then could be used to guide hit-to-
lead optimization. 
    To date, our focus has been on inhibitors potency rather than selectivity or other biological 
properties such as pharmacokinetics and cellular toxicity. Selectivity is an important issue to 
limit unexpected side effects mediated by off-target interactions; however, targeted favorable 
selectivity profile (pharmacology) is frequently serendipitous. Identifying the optimal 
selectivity profile for a given disease, cancer, would be important prior to conducting on the 
search for selective inhibitors. Analysis of biological data of small molecules entered into 
Phase I clinical trial might shed useful insights. Future work should also include the 
prediction of biological properties by computational modeling to aid progress towards clinical 
application. 
    Finally, it would be important to have a better understanding of in-house experimental 
thermal shift assay data (Figure 1). Qualitatively, there is a correlation between the binding 
affinity and the shift in protein melting temperature, but a supporting quantitative theoretic 
model is lacking. 
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Figure 1. Thermal shifts (ΔTm) show good correlation to binding affinities (ΔG) of four series 
of inhibitors measured on EphA3.
Page | 94                                                                                        
 
Acknowledgements 
 
    In 2008, I made an important decision in my life that I quit my job in a multinational 
company to pursue a PhD degree. I was immediately attracted by the topic “Drug Discovery 
by Computational Modeling” and was luckily accepted by Prof. Amedeo Caflisch to join his 
group and work with talents in University of Zurich. After the first happy and worriless year, 
the next year soon turned out to be the darkest ever in my life that I kept asking myself for a 
few months if I should quit. The change from an experimentalist to a computational scientist 
was just so hard, and obviously I severely underestimated the challenges in the field of drug 
discovery. I am so glad that I didn’t give up and finally have a chance to look back at what I 
have done in the last four years. 
    For this, I would like to express my sincere gratitude to Prof. Amedeo Caflisch for his 
continuous support, his great motivation and patience, as well as scientific commitment along 
these last four years. I would like to thank Dr. Danzhi Huang, a great mentor, for sharing his 
precious drug discovery experiences with me and the help in guiding me in the field of 
computer-aided drug design. Many thanks to them for offering me the opportunity to take an 
adventure in this exciting field, to which I shall dedicate my life. 
    I would like to thank Prof. Cristina Nevado and Dr. Karine Lafleur for the wonderful 
synthetic work on converting identified hits into potent and selective lead compounds, which 
is the source of confidence for my future work. I am thankful to Dr. Jing Dong for solving the 
crystal structures, which confirm the predictions. 
    I would like to thank all the members of the Caflisch group for motivating discussions and 
valuable advices. I am grateful to Dr. Philipp Schütz and Dr. Ting Zhou for help with 
computer related issues. Many thanks to Tim Knehans and Emilie Frugier for interesting 
discussions, and particularly to Dr. Andreas Vitalis for his annoying but yet scientifically 
critical comments from which I benefit a lot. 
    I would like to thank Prof. Huangxian Ju who expressed regret on my decision in 2005 for 
not continuing a PhD study, for his mentoring on my early scientific research. 
    Last but not least, I would like to thank my family especially my mother who always 
worries about me and complains that I run so far away from her. I want to thank my sister and 
her two beautiful daughters, all my friends, and the ladies with heart broken. 
                                                                                                                                        Page | 95 
 
Curriculum Vitae 
 
Personal 
Name     Hongtao Zhao 
Date of Birth    December 04, 1980 
Nationality    China 
 
Education 
Jan. 2009 - Present      PhD in Biochemistry, University of Zurich 
 Computer aided drug design 
Sep. 2002 - May. 2005      Master in Analytical Chemistry, Nanjing University                              
 Biosensor research 
Sep. 1998 - Jul. 2002      Bachelor in Chemistry, Nanjing University 
 
Employment 
May 2006 - Jul. 2008   GE (China) Research & Development Center Co., Ltd. 
 Analytical chemist 
Jun. 2005 - Apr. 2006   Simax technology Co., Ltd 
 Engineer  
 
Page | 96                                                                                        
 
Publications 
1. Zhao, H.; Caflisch, A. Discovery of novel classes of ZAP70 inhibitors by docking into a 
protein conformation generated by molecular dynamics. In preparation. 
2. Zhao, H.; Caflisch, A. Mr. Dock: molecular recognition in flexible docking of small 
molecules to proteins. In preparation. 
3. Zhao, H.; Dong, J.; Lafleur, K.; Nevado, C.; Caflisch, A. Discovery of a novel chemotype 
of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics. Acs 
Med Chem Lett 2012, 3, 834-8. 
4. Zhao, H.; Huang, D.; Caflisch, A. Discovery of tyrosine kinase inhibitors by docking into 
an inactive kinase conformation generated by molecular dynamics. ChemMedChem 2012, 
7, 1983-90. 
5. Zhao, H.; Huang, D. Hydrogen bonding penalty upon ligand binding. PLoS One 2011, 6, 
e19923.    
6. Messner, S.; Altmeyer, M.; Zhao, H.; Pozivil, A.; Roschitzki, B.; Gehrig, P.; Rutishauser, 
D.; Huang, D.; Caflisch, A.; Hottiger, M. O. PARP1 ADP-ribosylates lysine residues of 
the core histone tails. Nucleic Acids Res 2010, 38, 6350-62. 
 
Software 
1. Developed software Mr. Dock for fast and accurate flexible docking.  
2. Developed software LIBO for in silico fragment-based drug design (FBDD), with 
functions including automatic fragmentation of a compound library, pharmacophore 
filtering and substructure search. 
3. Developed software Hydro for monitoring change in hydrogen bonding network upon 
ligand binding.  
 
 
